Literature DB >> 7920523

[Estimation of benefits and risks of the treatment of rheumatoid polyarthritis with glucocorticoids using the health-related quality of life measurements].

M B Ferraz1, M R Quaresma, C H Goldsmith, K Bennett, E Atra.   

Abstract

The purpose of this study was to use the utility approach to evaluate the risks and benefits of corticosteroid therapy in rheumatoid arthritis patients. The utility approach provides us with a quantitative measure of the value or preference a patient attaches to his overall health status defined on a scale from perfect health (1) to death (0). Benefits and toxicity are combined into a number reflecting the patients combined assessment of the benefits of treatment and the side-effects associated with it. Utility of 3 scenarios (rheumatoid arthritis patients treated respectively with no, 5 mg/day and 15 mg/day of prednisone) were determined through the time trade-off (TTO) and thermometer scale (TS) techniques. Twenty-five rheumatoid arthritis patients selected at random among subjects attending an outpatient clinic and 25 rheumatologists were interviewed using visual aids. Treatment with 15 mg/d prednisone was assigned the highest utilities by both patients and physicians. Coefficients of correlation between thermometer scale and time trade-off utilities were 0.675 (p < 0.01) for physician-assigned utilities and 0.518 (p < 0.05) for patient-assigned utilities. Medical decisions concerning rheumatoid arthritis patients should take into account the preferences of patients and physicians.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7920523

Source DB:  PubMed          Journal:  Rev Rhum Ed Fr        ISSN: 1169-8330


  2 in total

1.  Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis.

Authors:  G J Tijhuis; S J Jansen; A M Stiggelbout; A H Zwinderman; J M Hazes; T P Vliet Vlieland
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  Measuring utilities by the time trade-off method in Tunisian rheumatoid arthritis patients.

Authors:  Ismail Bejia; Kamel Ben Salem; Mongi Touzi; Naceur Bergaoui
Journal:  Clin Rheumatol       Date:  2005-05-18       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.